New developments in the management of nasopharyngeal carcinoma

被引：12

作者：

Blanchard, P. ^{[1
,2
]}

Nguyen, F. ^{[1
]}

Moya-Plana, A. ^{[3
]}

Pignon, J. P. ^{[2
,4
]}

Even, C. ^{[3
]}

Bidault, F. ^{[5
]}

Temam, S. ^{[3
]}

Ruffier, A. ^{[1
]}

Tao, Y. ^{[1
]}

机构：

[1] Gustave Roussy Canc Campus, Dept Radiotherapie Oncol, 114 Rue Edouard Valliant, F-94800 Villejuif, France

[2] Univ Paris Saclay, Unite Inserm 1018, CESP, F-94800 Villejuif, France

[3] Gustave Roussy Canc Campus, Dept Carcinol Cervicofaciale, F-94800 Villejuif, France

[4] Gustave Roussy Canc Campus, Serv Biostatist & Epidemiol, Plateforme LNCC Metaanal, F-94800 Villejuif, France

[5] Gustave Roussy Canc Campus, Serv Imagerie Med, F-94800 Villejuif, France

来源：

CANCER RADIOTHERAPIE | 2018年 / 22卷 / 6-7期

关键词：

Nasopharyngeal cancer; Chemotherapy; Epstein Barr virus; Meta-analysis; Radiotherapy; EPSTEIN-BARR-VIRUS; TARGET VOLUMES CTV; CONCURRENT CHEMORADIOTHERAPY; RADIOTHERAPY; DNA; CHEMOTHERAPY; MULTICENTER; DELINEATION; CANCER; TRIAL;

D O I：

10.1016/j.canrad.2018.06.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Nasopharyngeal carcinoma is a rare condition, with less than 300 cases occurring per year in France. Its treatment can be difficult due to the importance of side effects, but tumor control is usually excellent following a well conducted chemoradiotherapy. This article summarizes the recent advances in nasopharyngeal cancer diagnosis, classification, treatment, surveillance and management of recurrences. Chemotherapy timing is discussed, along with arguments in favor of induction chemotherapy in locally advanced cases. As a survival advantage has been suggested for when patients are treated in high volume center it seems reasonable to refer these young patients for treatment to tertiary expert centers, especially given the low incidence of the disease. (C) 2018 Societe francaise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

引用

页码：492 / 495

页数：4

共 24 条

[1] Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099
Al-Sarraf, M
LeBlanc, M
Giri, PGS
Fu, KK
Cooper, J
Vuong, T
Forastiere, AA
Adams, G
Sakr, WA
Schuller, DE
Ensley, JF
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1310 - 1317
[2] Proton Therapy for Head and Neck Cancers
Blanchard, Pierre
Gunn, Gary Brandon
Lin, Alexander
Foote, Robert L.
Lee, Nancy Y.
Frank, Steven J.
[J]. SEMINARS IN RADIATION ONCOLOGY, 2018, 28 (01) : 53 - 63
[3] Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis
Blanchard, Pierre
Lee, Anne
Marguet, Sophie
Leclercq, Julie
Ng, Wai Tong
Ma, Jun
Chan, Anthony T. C.
Huang, Pei-Yu
Benhamou, Ellen
Zhu, Guopei
Chua, Daniel T. T.
Chen, Yong
Mai, Hai-Qiang
Kwong, Dora L. W.
Cheah, Shie Lee
Moon, James
Tung, Yuk
Chi, Kwan-Hwa
Fountzilas, George
Zhang, Li
Hui, Edwin Pun
Lu, Tai-Xiang
Bourhis, Jean
Pignon, Jean Pierre
[J]. LANCET ONCOLOGY, 2015, 16 (06) : 645 - 655
[4] A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT).
Chan, Anthony T. C.
Hui, Edwin Pun
Ngan, Roger K. C.
Tung, Stewart Yuk
Cheng, Ashley Chi Kin
Ng, Wai Tong
Lee, Victor H. F.
Ma, Brigette
Cheng, Hoi Ching
Wong, Frank C. S.
Loong, Herbert H. F.
Tong, Macy
Poon, Daren M. C.
Ahuja, Anil Tejbhan
King, Ann Dorothy
Wang, Ki
Mo, Frankie
Zee, Benny C. Y.
Chan, Allen K. C.
Lo, Y. M. Dennis
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5] Chan KCA, 2017, NEW ENGL J MED, V377, P513, DOI [10.1056/NEJMoa1701717, 10.1056/nejmoa1701717]
[6] The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: A need for reappraisal
Chang, Cindy M.
Yu, Kelly J.
Mbulaiteye, Sam M.
Hildesheim, Allan
Bhatia, Kishor
[J]. VIRUS RESEARCH, 2009, 143 (02) : 209 - 221
[7] Concurrent Chemoradiotherapy vs Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: Phase III Randomized Trial
Chen, Qiu-Yan
Wen, Yue-Feng
Guo, Ling
Liu, Huai
Huang, Pei-Yu
Mo, Hao-Yuan
Li, Ning-Wei
Xiang, Yan-Qun
Luo, Dong-Hua
Qiu, Fang
Sun, Rui
Deng, Man-Quan
Chen, Ming-Yuan
Hua, Yi-Jun
Guo, Xiang
Cao, Ka-Jia
Hong, Ming-Huang
Qian, Chao-Nan
Mai, Hai-Qiang
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (23): : 1761 - 1770
[8] A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)
Frikha, M.
Auperin, A.
Tao, Y.
Elloumi, F.
Toumi, N.
Blanchard, P.
Lang, P.
Sun, S.
Racadot, S.
Thariat, J.
Alfonsi, M.
Tuchais, C.
Cornely, A.
Moussa, A.
Guigay, J.
Daoud, J.
Bourhis, J.
[J]. ANNALS OF ONCOLOGY, 2018, 29 (03) : 731 - 736
[9] Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines
Gregoire, Vincent
Evans, Mererid
Quynh-Thu Le
Bourhis, Jean
Budach, Volker
Chen, Amy
Eisbruch, Abraham
Feng, Mei
Giralt, Jordi
Gupta, Tejpal
Hamoir, Marc
Helito, Juliana K.
Hu, Chaosu
Hunter, Keith
Johansen, Jorgen
Kaanders, Johannes
Laskar, Sarbani Ghosh
Lee, Anne
Maingon, Philippe
Makitie, Antti
Micciche, Francesco
Nicolai, Piero
O'Sullivan, Brian
Poitevin, Adela
Porceddu, Sandro
Skiadowski, Krzysztof
Tribius, Silke
Waldron, John
Wee, Joseph
Yao, Min
Yom, Sue S.
Zimmermann, Frank
Grau, Cai
[J]. RADIOTHERAPY AND ONCOLOGY, 2018, 126 (01) : 3 - 24
[10] Holliday E., 2015, INT J PARTICLE THER, V2, P19, DOI [10.14338/IJPT-15-00011.1, DOI 10.14338/IJPT-15-00011.1]

← 1 2 3 →